Article 12 Oct 2023 10 Years After Actavis, The Cases That Follow Tell A Story United States Anti-trust
Article 02 Oct 2023 D.C. Circuit Dismisses FTC Antitrust Suit: Exclusive Pharma Patent Licenses Remain Permissible Under The Patent Act United States Anti-trust
Article 19 Aug 2022 SEP Enforcement: Has The Biden Administration Tabled A Revised Policy Statement? United States IP
Article 03 Dec 2021 Xryem: Pharmaceutical Settlement Acceleration Clause Found Anticompetitive Due To Risk Of "Profit Crushing Competition" United States Anti-trust
Article 22 Oct 2021 The Sham Litigation Exception After AbbVie - Is The Subjective Element A Sham? United States Anti-trust
Article 12 Oct 2021 FDA Acting Commissioner Of Food And Drugs Seeks Collaboration Between FDA And USPTO To Address Pharmaceutical Patent-Related Matters Affecting Competition United States IP
Article 19 Aug 2021 Federal Circuit Clarifies The Scope Of Its Jurisdiction Over Walker Process Antitrust Claims In Chandler. v. Phoenix Services LLC United States IP
Article 18 Aug 2021 Can Biologics Manufacturers Face Antitrust Risk For Pointing Out That Biosimilars Are Different? United States Anti-trust
Article 16 May 2017 Pharmaceutical Antitrust Update: Courts Address How And When Product Hopping May Violate The Antirust Laws United States Anti-trust